Our latest #axSpA podcast is now available for viewing on the #IMIDForum. 🎧Listen today to access valuable insights from industry experts on some of the latest publications in #rheumatology ow.ly/FV7y50WoaZe

Our latest #axSpA literature highlights, featuring research by Pons, et al. are now live on the #IMIDForum. 📰📰 👉Access these comprehensive slide decks for the latest insights in axSpA treatment: ow.ly/2TPN50Wmb0I

🔔Stay informed with our latest #PsA literature highlights and detailed slide decks. 👉Now available for free on the #IMIDForum: ow.ly/Lmst50Wkjzl

Data presented by Smolen et al. support the potential of #UPA monotherapy as a treatment option for patients with moderately to severely active #RA who have responded inadequately to #MTX. Find out more here: ow.ly/o36s50WgKLu

Heiting et al. report that patients with #axSpA paradoxically form and resorb bone; while #secukinumab improved symptoms, it did not reverse skeletal deficits over 2 years. 👇👇 ow.ly/42Qz50Wmb2U

Palsson et al. report a considerable proportion of #PsA patients receiving b/tsDMARDs never achieve remission and approximately half never achieve sustained remission. 📑 👉Get the full summary here: ow.ly/Grul50WkjHb #IMIDForum

In patients with moderate-to-severely active UC, obefazimod 50mg QD demonstrated durable efficacy over 96 weeks in a Phase 2b open-label maintenance study. 👉Head over to #IMIDForum to see the latest data from Vermeire, et al. and read the summary slides for free.

👉Enhance your understanding of #PsA with our newly uploaded slide deck and literature highlights. Visit the #IMIDForum today to access these free resources: ow.ly/CHCC50WkjAu

👉Our July literature search identified 22 new papers on #IBD! 👀 View the results by clicking the link below: imidforum.com/resources

👉Our July literature search identified 82 new papers on #PsO! 👀 View the results by clicking the link below: ow.ly/k1zX50WwzuS

Enhance your understanding of #axSpA with our newly uploaded slide deck and literature highlights. 📑 👉Visit the #IMIDForum today to access these free resources: ow.ly/Rh5S50Wmb3v

Long-term efficacy and safety of UPA in patients with moderately to severely active UC. Does the latest data from Panaccione, et al. hold the potential to more insight into the risk-benefit profile for UPA. #Gastro 🔔Keep up to date in #UC at ow.ly/kt2U50Wr94f

Disease activity measures such as CRP, ASDAS, and DAPSA improved in all groups on #secukinumab. Improvements were most pronounced in b/tsDMARD-naïve patients and sustained through 48 months, as shown by Pons et al. See the insights from the #IMIDForum: ow.ly/PxzA50Wmb4k

Prevalence and predictors of ever achieving remission and sustained remission in #PsA patients receiving b/tsDMARDs, using three different remission criteria was evaluated by Palsson et al. 🔎Find out more from this paper over on the #IMIDForum. ow.ly/B4Kx50WkjEP

No statistically significant increase in new-onset IBD was observed for bimekizumab, secukinumab, brodalumab, or ustekinumab. 💡 Learn more here: ow.ly/Rt5Z50Wrbjg

🔎Discover the newest findings in #PsA in our latest literature highlights. Enhance your clinical knowledge with free access on the #IMIDForum: ow.ly/shBE50WkjBN

AxSpA is linked to poor skeletal health; while IL-17 blockade improves symptoms, its impact on bone is unknown. This study by Heiting et al. used HR-pQCT to assess effects of #secukinumab on bone health. 🔎Find more on this paper over on the #IMIDForum. ow.ly/NZmr50Wmb5I

🔎Dive into the latest research on #RA with our new in-depth slide decks and literature highlights! ⭐Available now for free on the #IMIDForum: imidforum.com/publications

New Podcast! 📣 July's edition of the Discussing #RA Podcast with Professor Iain McInnes is now available on the #IMIDForum imidforum.com/podcasts/episo…

Most patients who entered the #LTE with clinical remission per adapted Mayo score maintained clinical remission at Weeks 48 and 96. 🔎Head over to #IMIDForum to see the latest data from Panaccione, et al. and read the summary slides for free. ow.ly/EHZ650Wr93m